Literature DB >> 31157605

Association Between Dietary Selenium Intake and the Prevalence of Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study.

Jing Wu1, Chao Zeng2, Zidan Yang1, Xiaoxiao Li3, Guanghua Lei3,4,5, Dongxing Xie4, Yilun Wang4, Jie Wei2,6, Tubao Yang1.   

Abstract

Objective: The aim was to examine the association between dietary selenium intake and nonalcoholic fatty liver disease (NAFLD) in a large group of middle-aged and elderly Chinese persons.Method: The data included in this analysis were from a population-based study, the Xiangya Hospital Health Management Center Study. NAFLD was diagnosed by (1) imaging or histological evidence of hepatic steatosis; (2) absence of specific etiologies of NAFLD; and (3) no heavy consumption of alcohol. Dietary selenium intake was assessed using a validated semi-quantitative food frequency questionnaire. The association between dietary selenium intake and the prevalence of NAFLD was evaluated using logistic and spline regression in a cross-sectional study of 5436 subjects.
Results: The prevalence of NAFLD was 36.8%. Compared with the lowest quintile, the energy-adjusted odds ratios for NAFLD were 1.27 (95% confidence interval [CI], 1.07-1.52), 1.30 (95% CI, 1.09-1.55), and 1.58 (95% CI, 1.33-1.89) for the third, fourth, and fifth quintiles of selenium intake, respectively, and there was a positive dose-response relationship (r = 0.88, p for trend = 0.008). Similar results were observed for men and women separately. The findings were not materially altered by adjustment for potential confounders (i.e., age, gender, body mass index, smoking status, diabetes, hypertension, activity level, nutritional supplements, energy intake, fat intake, fiber intake, cholesterol and saturated fatty acid intake).Conclusions: In this middle-aged and elderly population, subjects with higher dietary selenium intake, even below the recommended nutrient intake in China, had higher prevalence of NAFLD in a dose-response relationship manner.

Entities:  

Keywords:  Selenium; cross-sectional study; dietary; dose–response; fatty liver

Mesh:

Substances:

Year:  2019        PMID: 31157605     DOI: 10.1080/07315724.2019.1613271

Source DB:  PubMed          Journal:  J Am Coll Nutr        ISSN: 0731-5724            Impact factor:   3.169


  7 in total

1.  Cross-sectional analysis of the health profile and dietary intake of a sample of Canadian adults diagnosed with non-alcoholic fatty liver disease.

Authors:  Michelle L Aktary; Lindsay K Eller; Alissa C Nicolucci; Raylene A Reimer
Journal:  Food Nutr Res       Date:  2020-09-18       Impact factor: 3.894

2.  Serum selenium and non-alcoholic fatty liver disease (NAFLD) in U.S. adults: National Health and Nutrition Examination Survey (NHANES) 2011-2016.

Authors:  Xin Wang; Young Ah Seo; Sung Kyun Park
Journal:  Environ Res       Date:  2021-04-16       Impact factor: 8.431

Review 3.  Changes in Glutathione Content in Liver Diseases: An Update.

Authors:  Mariapia Vairetti; Laura Giuseppina Di Pasqua; Marta Cagna; Plinio Richelmi; Andrea Ferrigno; Clarissa Berardo
Journal:  Antioxidants (Basel)       Date:  2021-02-28

4.  Selenotranscriptome Network in Non-alcoholic Fatty Liver Disease.

Authors:  Kaitlin Day; Lucia A Seale; Ross M Graham; Barbara R Cardoso
Journal:  Front Nutr       Date:  2021-11-17

Review 5.  Selenium Status in Patients with Chronic Liver Disease: A Systematic Review and Meta-Analysis.

Authors:  Yaduan Lin; Fanchen He; Shaoyan Lian; Binbin Xie; Ting Liu; Jiang He; Chaoqun Liu
Journal:  Nutrients       Date:  2022-02-23       Impact factor: 5.717

6.  The association between non-alcoholic fatty liver disease (NAFLD) and advanced fibrosis with blood selenium level based on the NHANES 2017-2018.

Authors:  Jie Liu; Liao Tan; Zhaoya Liu; Ruizheng Shi
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

7.  Association between egg consumption and metabolic syndrome in Chinese population: a cross-sectional study.

Authors:  Ziying Wu; Dongxing Xie; Haochen Wang; Wanchun Wang; Minren Shen; Zidan Yang; Ning Wang; Zhenglei Zhu
Journal:  BMJ Open       Date:  2021-12-24       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.